#SGLT2I

Swapnil Hiremath, MD, MPH

hswapnil

why do we get natriuresis with SGLT2i? Could it just be the simple fact that the 'S' in SGLT2i stands for sodium - so blocking sodium reabsorbtion in PT =

ChristosArgyropoulos

ChristosArgyrop

My prescription guide of #SGLT2I - as an early adopter since late 2015 4+1 tweets which can kick start your career as a slayer of diabetic kidney disease, savior of

ChristosArgyropoulos

ChristosArgyrop

Alright then, time to visit this. We currently have two publications for two different SGLT2i from two different studies (CANVAS and EMPAREG-Outcome) that show that the *relative* benefits of SGLT2i

Jacob de Wolff

jfdwolff

Last talk: Dr Tahseen Chowdhury @NHSBartsHealth about new diabetes therapies. #AGMConfUK Diabetes worldwide 400 million and rising. Linear increase in the UK. 1:4 hospital inpatients have diabetes. Main problem is

Aisha Shaikh

aishaikh

SGLT2 Inhibitors as Diuretics:Tweetorial SGLT2i: how is it’s diuretic effect potentially different from the Loop Diuretics?1/@RenalFellowNtwk @NephJC#NephJC #SGLT2i Let’s start with a Poll:Loop Diuretics inhibit the Tubuloglomerular Fe

Dr priti MD

priti899

SGLT2i are emerging as a promising agent to prevent and the progression of DKDEver wonderedWhat do they do to electrolytesWhy r these diuretics not associated with electrolyte depletionLet's dive

ChristosArgyropoulos

ChristosArgyrop

This 40% reduction of worsening renal function/need for dialysis seen in the SGLT2i trials (which included pts with Diabetes Type 2, except DAPA-HF/EMPEROR) has some rather implications for the business

ChristosArgyropoulos

ChristosArgyrop

Had some more time with the clinical trials EMPEROR-Reduced and DAPA-CKD and was able to compute various composite outcomes from the major SGLT2i trials. Just posting the results here :

Brendon Neuen

brendonneuen

Almost all guidelines recommend SGLT2i as 2nd line in T2DM & CKD/HF if not achieving glucose control on metforminBut should “metformin 1st for all” be revisited given the latest trial

Juan Carlos Q Velez

VelezNephHepato

Today, I was asked by a #medicalstudent what are the most exciting developments in nephrology in the last few years, things that have affected the way I practice. Gave a

Sarah Hudson

sarahhudsonuk

My top 10 learning points from the #ESCCongressA thread for cardiologists/general physicians1) Post acute MI, transfuse if ≤8g/dL Evidence: REALITY trial- not yet published – summary reported https://www.acc.org/latest-in-cardiology/cli